Business Context and Reporting Period
This Form 8-K was filed by Medtronic Plc on July 17, 2017, to clarify information regarding its first quarter and full fiscal year 2018 financial expectations. The filing addresses recent news articles and confirms the status of an information technology (IT) disruption that occurred in June 2017.
Key Financial Metrics and Guidance
The filing provides specific forward-looking guidance on a constant currency basis:
- Fiscal Q1 2018 Revenue Growth: Reiterated at 4-5%, with expectations for growth at the lower end of this range due to the IT disruption and temporary sensor supply limitations in the Diabetes Group.
- Fiscal Q1 2018 Adjusted Diluted EPS Growth: Reiterated at the upper end of the high-single digit range, supported by underlying business strength and expected tax benefits.
- Fiscal Year 2018 Revenue Growth: Reiterated at 4-5%.
- Fiscal Year 2018 Adjusted Diluted EPS Growth: Reiterated at 9-10%.
The filing does not provide specific values for total revenue, profit, cash flow, margins, debt, or liquidity for the current period.
Material Changes and Operational Context
Medtronic confirmed that its IT systems, which were disrupted in June 2017, have been fully restored. The Company attributes the incident to an internal technical infrastructure issue and does not believe it will materially affect fiscal year 2018 results. However, the disruption and strong demand for new products in the Diabetes Group have created a temporary supply constraint for sensors, influencing the Q1 revenue outlook to the lower end of the guidance range.
Outlook, Risks, and Contingencies
Management expressed confidence in the Company's robust pipeline and customer reception of innovative products. The current guidance excludes the impact of the previously announced divestiture of a portion of the Patient Monitoring and Recovery division to Cardinal Health, which is expected to close in the second fiscal quarter. Guidance will be updated following the transaction's closing.
Standard risks cited include competitive factors, product development delays, third-party collaboration challenges, IT disruptions, regulatory changes, and foreign currency fluctuations. The Company notes that forward-looking non-GAAP measures exclude foreign currency impacts and potential charges related to amortization, acquisitions, taxes, litigation, and restructuring.
Key Facts for Investor Verification
- Confirmation that the June 2017 IT disruption has been resolved with no expected material impact on full-year results.
- Reiteration of fiscal 2018 revenue growth guidance at 4-5% and adjusted diluted EPS growth at 9-10% on a constant currency basis.
- Expectation of Q1 revenue growth at the lower end of the 4-5% range due to temporary sensor supply constraints.
- Anticipated closing of the Patient Monitoring and Recovery division divestiture to Cardinal Health in Q2 2018, which will trigger a guidance update.
- Exclusion of foreign currency fluctuations and specific non-GAAP adjustments from the provided growth percentages.